IAM
TRVI icon

Innovis Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Innovis Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-43,232
Closed -$103K – 179
2023
Q2 		$103K Sell
43,232
-44,137
-51% -$111K 0.04% 159
2023
Q1 		$162K Sell
87,369
-84
-0.1% -$190 0.07% 152
2022
Q4 		$169K Buy
+87,453
New +$172K 0.08% 143

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Innovis Asset Management's TRVI Position: Q3 2023 in Review

Innovis Asset Management sold out of Trevi Therapeutics (TRVI) in Q3 2023, closing a stake of 43,232 shares — an estimated $103K sold.

Innovis Asset Management first reported a position in TRVI in Q4 2022 and held it in 3 quarters. The position peaked at $169K in Q4 2022. 55 funds tracked by Wall St. Rank hold TRVI as of Q3 2023.

  • Innovis Asset Management reported no remaining Trevi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Innovis Asset Management sold 43,232 Trevi Therapeutics shares in Q3 2023, an estimated $103K.
  • Innovis Asset Management first reported a position in Trevi Therapeutics in Q4 2022 and held it in 3 quarters.
  • Innovis Asset Management's Trevi Therapeutics position peaked at $169K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.